Letter to the Editor Regarding “Treatment Persistence Among Anti–Tumor Necrosis Factor–experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti–Tumor Necrosis Factor Agent” | Publicación